AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$PRE

Yeung Danny Sheng Wu purchased $502K of PRE

Yeung Danny Sheng Wu (Chief Executive Officer) purchased 24,681 shares of Prenetics Global Ltd (PRE) at an average of $20.34 ($18.31–$21.40, $0.50M total) across 3 trades over 2026-08-20 to 2026-08-24.

Original reporting
SEC EDGAR · Yeung Danny Sheng Wu
Published Aug 25, 2026, 1:41 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 2:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PRE
Bullish
medium confidence
Mentioned
$PRE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PREBullishLow
01

Why it matters

The insider buy adds a modest positive signal but is unlikely to drive significant price movement.

02

Market read

Primary insider purchase; modest relevance for short‑term traders monitoring PRE.

03

What to watch

Potential upcoming financing or strategic moves not disclosed could influence the significance of the buy.

Relevance 6/10Novelty 7/10Timing: after market close 2026-08-24

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$PREBullishMedium confidence
Context

CEO Yeung Danny Sheng Wu bought 24,681 shares for $502K, increasing his stake to 112,416 shares.

Expected impact

Potential slight upside pressure in the near term as investors view the buy as a confidence signal.

Evidence & confidence

Form 4 filing is a primary source; the purchase size is modest relative to market cap, limiting impact.

Market effects

Sector

Minimal; insider activity does not materially affect the broader biotech/genomics sector.

Regional

Limited to investors tracking PRE; no broader regional effect.

Global

Low; the filing is company‑specific and unlikely to move global markets.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement, limiting upside.

Key entities

  • Company
    Prenetics Global Ltd

    Listed biotech firm (ticker PRE) whose CEO made the purchase.

  • Individual
    Yeung Danny Sheng Wu

    Chief Executive Officer of Prenetics Global Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PRE insider trading history →

Related articles

AUG 25
$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

yahoo.com2 min
AUG 18
$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

yahoo.com7 min
AUG 18
$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.

finanznachrichten.de6 min
JUL 30
$PREMed

PartnerRe records $447m in first-half net income

PartnerRe reported first-half 2026 net income of $447 million, down from $493 million a year earlier, with operating income of $689 million and annualised operating ROE of 12.6%. Gross premiums written rose to $5.42 billion. Non-life underwriting profit was $396 million with a 85.1% combined ratio. Investment income increased to $491 million, but unrealised losses reduced net investment return.

royalgazette.com4 min